Education
About Us
Working with TipRanks
Follow Us
EIS - ETF AI Analysis
Top Page
iShares MSCI Israel ETF (EIS)
Rating:61Neutral
Price Target:
$105.00
Positive Factors
Strong Top Holdings
Several key holdings, such as Leumi, Poalim, and Elbit Systems, have delivered strong year-to-date performance, supporting the ETF’s overall gains.
Sector Diversification
The ETF is spread across multiple sectors, including financials, technology, and health care, reducing reliance on any single industry.
Healthy Year-to-Date Performance
The fund has shown solid year-to-date growth, indicating strong overall momentum in its portfolio.
Negative Factors
High Geographic Concentration
The ETF is heavily focused on Israel, with limited exposure to other regions, increasing vulnerability to local economic or geopolitical risks.
Underperforming Holding
Teva Pharmaceutical, one of the top holdings, has shown negative year-to-date performance, which may drag on the fund’s returns.
Above-Average Expense Ratio
The ETF’s expense ratio is higher than many other funds, which could reduce long-term returns for investors.
EIS vs. SPDR S&P 500 ETF (SPY)
AUM493.72M
RegionMiddle East & Africa
Expense Ratio0.59%
Beta0.77
IssueriShares
Inception DateMar 26, 2008
Dividend Yield1.02%
Asset ClassEquity
Index TrackedMSCI Israel Capped Index
Share Statistics
EPS (TTM)N/A
Shares OutstandingN/A
10 Day Avg. Volume83,964
30 Day Avg. Volume58,305
Financial Highlights & Ratios
PEG RatioN/A
Price to Book (P/B)N/A
Price to Sales (P/S)N/A
P/FCF RatioN/A
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
EPS Forecast (FY)N/A
Revenue Forecast (FY)N/A
EIS Summary
The iShares MSCI Israel ETF (EIS) is an investment fund that focuses on Israeli companies across various industries, including technology, healthcare, and finance. It follows the MSCI Israel Capped Index, which represents the overall Israeli market. Some well-known companies in this ETF include Teva Pharmaceutical and CyberArk Software. Investors might consider EIS for diversification and exposure to Israel’s innovative economy, known for its strong tech sector and growth potential. However, new investors should be aware that the ETF’s performance can be affected by fluctuations in the Israeli market and global economic conditions.
How much will it cost me?The iShares MSCI Israel ETF (EIS) has an expense ratio of 0.59%, meaning you’ll pay $5.90 per year for every $1,000 invested. This is higher than average for ETFs because it is passively managed but focuses on a niche market, which can involve higher costs to track the index effectively.
What would affect this ETF?The iShares MSCI Israel ETF (EIS) could benefit from Israel's strong presence in technology and healthcare, sectors known for innovation and growth potential. However, challenges such as geopolitical tensions in the Middle East or changes in global interest rates affecting financial institutions could negatively impact the ETF's performance. Investors should also consider how broader economic conditions and regulatory changes in Israel might influence its top holdings, including major banks and tech companies.
EIS Top 10 Holdings
The iShares MSCI Israel ETF (EIS) leans heavily on financials and technology, with banks like Leumi and Poalim rising steadily thanks to strong financial performance and attractive valuations. Mizrahi Tefahot and Phoenix are also bright spots, driving gains with robust growth and positive technical trends. However, tech names like CyberArk and Check Point are lagging, weighed down by bearish technical indicators and valuation concerns. This fund’s focus on Israel’s dynamic economy, particularly its financial and tech sectors, offers a compelling growth story, though some tech holdings may need time to regain momentum.
Name | Company Name | Weight % | Market Value | Market Cap | Yearly Gain | Overall Rating |
|---|---|---|---|---|---|---|
| Leumi | 9.15% | $46.13M | 102.92B | 81.74% | 82 Outperform | |
| Teva Pharmaceutical | 8.31% | $41.93M | $28.74B | 48.41% | 63 Neutral | |
| Poalim | 7.79% | $39.32M | 90.96B | 83.38% | 80 Outperform | |
| CyberArk Software | 6.19% | $31.23M | $22.36B | 36.54% | 52 Neutral | |
| Check Point | 4.66% | $23.48M | $19.89B | 0.20% | 76 Outperform | |
| Elbit Systems | 3.89% | $19.60M | 73.75B | 86.88% | 78 Outperform | |
| Discount | 3.77% | $19.01M | 41.22B | 53.33% | 79 Outperform | |
| Tower | 3.20% | $16.12M | 34.16B | 100.77% | ― | |
| Mizrahi Tefahot | 3.19% | $16.06M | 58.59B | 101.48% | 80 Outperform | |
| Phoenix | 2.84% | $14.33M | 34.47B | 210.84% | 81 Outperform |
EIS Technical Analysis
Positive
―
Price Trends
100.26
Positive
96.90
Positive
88.72
Positive
Market Momentum
0.50
Positive
50.09
Neutral
17.20
Positive
Evaluating momentum and price trends is crucial in ETF analysis to make informed investment decisions. For EIS, the sentiment is Positive. The current price of undefined is equal to the 20-day moving average (MA) of 103.14, equal to the 50-day MA of 100.26, and equal to the 200-day MA of 88.72, indicating a neutral trend. The MACD of 0.50 indicates Positive momentum. The RSI at 50.09 is Neutral, neither overbought nor oversold. The STOCH value of 17.20 is Positive, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Positive sentiment for EIS.
EIS Peer Comparison
Comparison Results
Performance Comparison
EIS
iShares MSCI Israel ETF
102.11
29.57
40.76%
TOUS
T. Rowe Price International Equity ETF
―
―
―
FNDB
Schwab Fundamental US Broad Market Index ETF
―
―
―
QEFA
SPDR MSCI EAFE StrategicFactors ETF
―
―
―
SUSL
iShares ESG MSCI USA Leaders ETF
―
―
―
ISRA
VanEck Israel ETF
―
―
―
Glossary
BuyAn ETF rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the ETF is likely to deliver higher returns compared to other ETFs in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
HoldAn ETF rated as a "Hold" s expected to perform in line with the overall market or a specific benchmark. This rating indicates that the ETF is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
SellAn ETF rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the ETF may deliver lower returns compared to other ETFs in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
Disclaimer
This AI Analyst ETF Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in ETFs carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.Date of analysis: ―
Table of Contents